Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection

Diabetes

Volumn 62, Issue 5, 2013, Pages 1665-1675

  Vergani, Andrea ^a,b   Fotino, Carmen ^c   D'Addio, Francesca ^b   Tezza, Sara ^a   Podetta, Michele ^c   Gatti, Francesca ^a   Chin, Melissa ^a   Bassi, Roberto ^a   Molano, Ruth D ^c   Corradi, Domenico ^d   Gatti, Rita ^d   Ferrero, Maria E ^e   Secchi, Antonio ^b,f   Grassi, Fabio ^g   Ricordi, Camillo ^c   Sayegh, Mohamed H ^a   Maffi, Paola ^b   Pileggi, Antonello ^c   Fiorina, Paolo ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF MIAMI   (United States)

^d UNIVERSITY OF PARMA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; PURINERGIC P2X RECEPTOR; PURINERGIC P2X1 RECEPTOR; PURINERGIC P2X7 RECEPTOR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL DAMAGE; CELL INFILTRATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; LONG TERM CARE; LYMPHOCYTE ACTIVATION; MALE; PANCREAS ISLET; PANCREAS ISLET GRAFT REJECTION; PANCREAS ISLET TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; TH1 CELL; TH17 CELL;

ADENOSINE TRIPHOSPHATE; ADULT; ANIMALS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; PURINERGIC P2X RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2X7; SIROLIMUS; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HETEROTOPIC; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 84876567309     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0242     Document Type: Article

References (47)

1. Bloomgarden ZT. Diabetes complications. Diabetes Care 2004;27:1506-1514 (Pubitemid 38680004)
2. Bloomgarden ZT. Consequences of diabetes: cardiovascular disease. Diabetes Care 2004;27:1825-1831 (Pubitemid 38857469)
3. Fiorina P, Shapiro AM, Ricordi C, Secchi A. The clinical impact of islet transplantation. Am J Transplant 2008;8:1990-1997
4. Venturini M, Fiorina P, Maffi P, et al. Early increase of retinal arterial and venous blood flow velocities at color Doppler imaging in brittle type 1 diabetes after islet transplant alone. Transplantation 2006;81:1274-1277 (Pubitemid 43804546)
5. Vantyghem MC, Kerr-Conte J, Arnalsteen L, et al. Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care 2009;32:1473-1478
6. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006;355:1318-1330 (Pubitemid 44465460)
7. Makhlouf L, Kishimoto K, Smith RN, et al. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes 2002;51:3202-3210 (Pubitemid 35246966)
8. Ricordi C, Strom TB. Clinical islet transplantation: advances and immunological challenges. Nat Rev Immunol 2004;4:259-268 (Pubitemid 38478661)
9. Bosi E, Braghi S, Maffi P, et al. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001;50:2464-2471 (Pubitemid 33642763)
10. Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 2003;196:85-108 (Pubitemid 37468106)
11. Murphy SP, Porrett PM, Turka LA. Innate immunity in transplant tolerance and rejection. Immunol Rev 2011;241:39-48
12. Shen X, Reng F, Gao F, et al. Alloimmune activation enhances innate tissue inflammation/injury in a mouse model of liver ischemia/reperfusion injury. Am J Transplant 2010;10:1729-1737
13. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 2011;11:201-212
14. Novak I. ATP as a signaling molecule: the exocrine focus. News Physiol Sci 2003;18:12-17 (Pubitemid 36299377)
15. Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009;461:282-286
16. Schenk U, Westendorf AM, Radaelli E, et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal 2008;1:ra6
17. Piccini A, Carta S, Tassi S, Lasiglié D, Fossati G, Rubartelli A. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc Natl Acad Sci USA 2008;105:8067-8072 (Pubitemid 351904709)
18. Homolya L, Steinberg TH, Boucher RC. Cell to cell communication in response to mechanical stress via bilateral release of ATP and UTP in polarized epithelia. J Cell Biol 2000;150:1349-1360
19. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998;50:413-492 (Pubitemid 28477681)
20. Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. Nature 2006;442:527-532 (Pubitemid 44167906)
21. Wilhelm K, Ganesan J, Müller T, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 2010;16:1434-1438
22. Casati A, Frascoli M, Traggiai E, Proietti M, Schenk U, Grassi F. Cell-autonomous regulation of hematopoietic stem cell cycling activity by ATP. Cell Death Differ 2011;18:396-404
23. Gabel CA. P2 purinergic receptor modulation of cytokine production. Purinergic Signal 2007;3:27-38
24. Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008;455:808-812
25. Yip L, Woehrle T, Corriden R, et al. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J 2009;23:1685-1693
26. Ferrari D, Pizzirani C, Adinolfi E, et al. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 2006;176:3877-3883 (Pubitemid 44264361)
27. Emamaullee JA, Davis J, Merani S, et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009;58:1302-1311
28. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008;205:3133-3144
29. Chadha R, Heidt S, Jones ND, Wood KJ. Th17: contributors to allograft rejection and a barrier to the induction of transplantation tolerance? Transplantation 2011;91:939-945
30. Schenk U, Frascoli M, Proietti M, et al. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal 2011;4:ra12
31. Murgia M, Hanau S, Pizzo P, Rippa M, Di Virgilio F. Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. J Biol Chem 1993;268:8199-8203 (Pubitemid 23120407)
32. Rizzo R, Ferrari D, Melchiorri L, et al. Extracellular ATP acting at the P2X7 receptor inhibits secretion of soluble HLA-G from human monocytes. J Immunol 2009;183:4302-4311
33. Fiorina P, Folli F, Maffi P, et al. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation 2003;75:1296-1301 (Pubitemid 36513037)
34. Vergani A, D'Addio F, Jurewicz M, et al. A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes 2010;59:2253-2264
35. Vergani A, Clissi B, Sanvito F, Doglioni C, Fiorina P, Pardi R. Laser capture microdissection as a new tool to assess graft-infiltrating lymphocytes gene pro file in islet transplantation. Cell Transplant 2009;18:827-832
36. Zahr E, Molano RD, Pileggi A, et al. Rapamycin impairs in vivo proliferation of islet beta-cells. Transplantation 2007;84:1576-1583
37. Petrelli A, Carvello M, Vergani A, et al. IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response. Diabetes 2011;60:3223-3234
38. Carvello M, Petrelli A, Vergani A, et al. Inotuzumab ozogamicin murine analog-mediated B-cell depletion reduces anti-islet allo- and autoimmune responses. Diabetes 2012;61:155-165
39. Fiorina P, Jurewicz M, Tanaka K, et al. Characterization of donor dendritic cells and enhancement of dendritic cell efflux with CC-chemokine ligand 21: a novel strategy to prolong islet allograft survival. Diabetes 2007;56:912-920 (Pubitemid 46525057)
40. Fiorina P, Vergani A, Petrelli A, et al. Metabolic and immunological features of the failing islet-transplanted patient. Diabetes Care 2008;31:436-438
41. Sutherland DE, Gruessner AC, Carlson AM, et al. Islet autotransplant outcomes after total pancreatectomy: a contrast to islet allograft outcomes. Transplantation 2008;86:1799-1802
42. Oberholzer J, Toso C, Ris F, et al. Beta cell replacement for the treatment of diabetes. Ann N Y Acad Sci 2001;944:373-387 (Pubitemid 34053323)
43. Shi Q, Lees JR, Scott DW, Farber DL, Bartlett ST. Endogenous expansion of regulatory T cells leads to long-term islet graft survival in diabetic NOD mice. Am J Transplant 2012;12:1124-1132
44. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-238 (Pubitemid 30490390)
45. Gulbransen BD, Bashashati M, Hirota SA, et al. Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis. Nat Med 2012;18:600-604
46. Arulkumaran N, Unwin RJ, Tam FW. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs 2011;20:897-915
47. Monti P, Scirpoli M, Maffi P, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 2008;118:1806-1814 (Pubitemid 351632383)